| Autor: |
Amnon Peled, Yaron Pereg, Eithan Galun, Ori Wald, Orly Eizenberg, Katia Beider, Lola Weiss, Devorah Olam, Yaniv Harel, Hanna Wald, Rinat Abramovitch, Neta Barashi, Ido D. Weiss, Elia Dery, Baruch Bulvik, Michal Abraham, Shiri Klein |
| Rok vydání: |
2023 |
| DOI: |
10.1158/0008-5472.c.6509951.v1 |
| Popis: |
CXCR4 expression in neuroblastoma tumors correlates with disease severity. In this study, we describe mechanisms by which CXCR4 signaling controls neuroblastoma tumor growth and response to therapy. We found that overexpression of CXCR4 or stimulation with CXCL12 supports neuroblastoma tumorigenesis. Moreover, CXCR4 inhibition with the high-affinity CXCR4 antagonist BL-8040 prevented tumor growth and reduced survival of tumor cells. These effects were mediated by the upregulation of miR-15a/16-1, which resulted in downregulation of their target genes BCL-2 and cyclin D1, as well as inhibition of ERK. Overexpression of miR-15a/16-1 in cells increased cell death, whereas antagomirs to miR-15a/16-1 abolished the proapoptotic effects of BL-8040. CXCR4 overexpression also increased miR-15a/16-1, shifting their oncogenic dependency from the BCL-2 to the ERK signaling pathway. Overall, our results demonstrate the therapeutic potential of CXCR4 inhibition in neuroblastoma treatment and provide a rationale to test combination therapies employing CXCR4 and BCL-2 inhibitors to increase the efficacy of these agents.Significance: These results provide a mechanistic rationale for combination therapy of CXCR4 and BCL-2 inhibitors to treat a common and commonly aggressive pediatric cancer.Cancer Res; 78(6); 1471–83. ©2017 AACR. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
